Which has stronger earnings & valuation, KALA or CALC?

CalciMedica is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio KALA BIO N/A N/A -$26.98M -$96.14 N/A CalciMedica N/A N/A -$29.56M -$1.31 N/A

Is KALA or CALC more profitable?

CalciMedica's return on equity of -863.40% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -1,336.10% -94.85% CalciMedica N/A -863.40% -144.33%

Do analysts rate INCR or CALC?

CalciMedica has a consensus price target of $10.00, suggesting a potential upside of 1,574.20%. Given CalciMedica's stronger consensus rating and higher possible upside, analysts clearly believe CalciMedica is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CalciMedica 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is INCR or CALC more profitable?

InterCure's return on equity of 0.00% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A CalciMedica N/A -863.40% -144.33%

Does the media favor INCR or CALC?

In the previous week, InterCure and InterCure both had 2 articles in the media. InterCure's average media sentiment score of 1.00 beat CalciMedica's score of 0.00 indicating that InterCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InterCure 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CalciMedica 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, TIL or CALC?

Instil Bio is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$7.08 N/A CalciMedica N/A N/A -$29.56M -$1.31 N/A

Is TIL or CALC more profitable?

Instil Bio's return on equity of -39.76% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -39.76% -22.38% CalciMedica N/A -863.40% -144.33%

Which has stronger valuation & earnings, CALC or PDSB?

PDS Biotechnology is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CalciMedica N/A N/A -$29.56M -$1.31 N/A PDS Biotechnology N/A N/A -$34.50M -$0.67 N/A

Is CALC or PDSB more profitable?

PDS Biotechnology's return on equity of -346.02% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets CalciMedica N/A -863.40% -144.33% PDS Biotechnology N/A -346.02% -102.36%

Is CALC or TLPH more profitable?

Talphera's return on equity of -92.98% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets CalciMedica N/A -863.40% -144.33% Talphera N/A -92.98% -53.22%

CalciMedica (CALC) Competitors

$0.60 -0.21 (-25.64%)

Closing price 04:00 PM Eastern

Extended Trading

$0.61 +0.01 (+1.96%)

As of 07:58 PM Eastern

Compare

CALC vs. KALA, INCR, TIL, PDSB, and TLPH

Should you buy CalciMedica stock or one of its competitors? MarketBeat compares CalciMedica with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CalciMedica include KALA BIO (KALA), InterCure (INCR), Instil Bio (TIL), PDS Biotechnology (PDSB), and Talphera (TLPH). These companies are all part of the "pharmaceutical products" industry.

How does CalciMedica compare to KALA BIO?

KALA BIO (NASDAQ:KALA) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

KALA BIO has a beta of -2.4, suggesting that its stock price is 340% less volatile than the broader market. Comparatively, CalciMedica has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

CalciMedica is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A

In the previous week, CalciMedica had 2 more articles in the media than KALA BIO. MarketBeat recorded 2 mentions for CalciMedica and 0 mentions for KALA BIO. KALA BIO's average media sentiment score of 0.00 equaled CalciMedica'saverage media sentiment score.

Company	Overall Sentiment
KALA BIO	Neutral
CalciMedica	Neutral

CalciMedica's return on equity of -863.40% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-1,336.10%	-94.85%
CalciMedica	N/A	-863.40%	-144.33%

24.6% of KALA BIO shares are owned by institutional investors. 2.2% of KALA BIO shares are owned by company insiders. Comparatively, 41.6% of CalciMedica shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

KALA BIO presently has a consensus target price of $1,018.75, suggesting a potential upside of 33,858.33%. CalciMedica has a consensus target price of $10.00, suggesting a potential upside of 1,574.20%. Given KALA BIO's higher probable upside, equities analysts plainly believe KALA BIO is more favorable than CalciMedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

KALA BIO and CalciMedica tied by winning 5 of the 10 factors compared between the two stocks.

How does CalciMedica compare to InterCure?

InterCure (NASDAQ:INCR) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

InterCure has higher revenue and earnings than CalciMedica. CalciMedica is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.70	-$10.37M	$0.03	33.33
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A

InterCure has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, CalciMedica has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

CalciMedica has a consensus price target of $10.00, suggesting a potential upside of 1,574.20%. Given CalciMedica's stronger consensus rating and higher possible upside, analysts clearly believe CalciMedica is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, InterCure and InterCure both had 2 articles in the media. InterCure's average media sentiment score of 1.00 beat CalciMedica's score of 0.00 indicating that InterCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InterCure	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CalciMedica	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

InterCure's return on equity of 0.00% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
CalciMedica	N/A	-863.40%	-144.33%

8.3% of InterCure shares are owned by institutional investors. 0.2% of InterCure shares are owned by insiders. Comparatively, 41.6% of CalciMedica shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

InterCure beats CalciMedica on 9 of the 13 factors compared between the two stocks.

How does CalciMedica compare to Instil Bio?

Instil Bio (NASDAQ:TIL) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Instil Bio has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market. Comparatively, CalciMedica has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

Instil Bio presently has a consensus target price of $66.00, suggesting a potential upside of 763.87%. CalciMedica has a consensus target price of $10.00, suggesting a potential upside of 1,574.20%. Given CalciMedica's stronger consensus rating and higher possible upside, analysts clearly believe CalciMedica is more favorable than Instil Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Instil Bio is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A

In the previous week, CalciMedica had 2 more articles in the media than Instil Bio. MarketBeat recorded 2 mentions for CalciMedica and 0 mentions for Instil Bio. Instil Bio's average media sentiment score of 0.00 equaled CalciMedica'saverage media sentiment score.

Company	Overall Sentiment
Instil Bio	Neutral
CalciMedica	Neutral

Instil Bio's return on equity of -39.76% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
CalciMedica	N/A	-863.40%	-144.33%

60.6% of Instil Bio shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by company insiders. Comparatively, 41.6% of CalciMedica shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

CalciMedica beats Instil Bio on 7 of the 12 factors compared between the two stocks.

How does CalciMedica compare to PDS Biotechnology?

CalciMedica (NASDAQ:CALC) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

CalciMedica has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market.

PDS Biotechnology is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

26.8% of PDS Biotechnology shares are held by institutional investors. 41.6% of CalciMedica shares are held by company insiders. Comparatively, 9.2% of PDS Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, CalciMedica had 2 more articles in the media than PDS Biotechnology. MarketBeat recorded 2 mentions for CalciMedica and 0 mentions for PDS Biotechnology. CalciMedica's average media sentiment score of 0.00 equaled PDS Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
CalciMedica	Neutral
PDS Biotechnology	Neutral

CalciMedica presently has a consensus price target of $10.00, indicating a potential upside of 1,574.20%. PDS Biotechnology has a consensus price target of $9.00, indicating a potential upside of 929.98%. Given CalciMedica's higher probable upside, analysts clearly believe CalciMedica is more favorable than PDS Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

PDS Biotechnology's return on equity of -346.02% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-144.33%
PDS Biotechnology	N/A	-346.02%	-102.36%

Summary

PDS Biotechnology beats CalciMedica on 7 of the 12 factors compared between the two stocks.

How does CalciMedica compare to Talphera?

CalciMedica (NASDAQ:CALC) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

CalciMedica currently has a consensus target price of $10.00, suggesting a potential upside of 1,574.20%. Talphera has a consensus target price of $3.00, suggesting a potential upside of 183.02%. Given CalciMedica's higher possible upside, analysts clearly believe CalciMedica is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, CalciMedica had 2 more articles in the media than Talphera. MarketBeat recorded 2 mentions for CalciMedica and 0 mentions for Talphera. CalciMedica's average media sentiment score of 0.00 equaled Talphera'saverage media sentiment score.

Company	Overall Sentiment
CalciMedica	Neutral
Talphera	Neutral

Talphera has higher revenue and earnings than CalciMedica. Talphera is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A
Talphera	$30K	1,833.80	-$14.29M	-$0.31	N/A

Talphera's return on equity of -92.98% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-144.33%
Talphera	N/A	-92.98%	-53.22%

37.7% of Talphera shares are held by institutional investors. 41.6% of CalciMedica shares are held by insiders. Comparatively, 3.5% of Talphera shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CalciMedica has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Talphera has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

Summary

Talphera beats CalciMedica on 8 of the 13 factors compared between the two stocks.

Get CalciMedica News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CALC vs. The Competition

Export

Metric	CalciMedica	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.69M	$3.49B	$6.54B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-0.46	11.34	21.43	22.01
Price / Sales	N/A	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	-1.30	8.26	10.76	6.41
Net Income	-$29.56M	$23.91M	$3.56B	$337.14M
7 Day Performance	-28.89%	3.05%	1.37%	-0.48%
1 Month Performance	-5.02%	2.40%	0.81%	0.49%
1 Year Performance	-63.80%	56.35%	30.53%	28.16%

CalciMedica Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CALC CalciMedica	1.3777 of 5 stars	$0.60 -25.6%	$10.00 +1,574.2%	-47.8%	$12.69M	N/A	N/A	30	News Coverage High Trading Volume
KALA KALA BIO	1.8286 of 5 stars	$2.85 -9.2%	$1,018.75 +35,645.6%	-98.4%	$52.98M	N/A	N/A	30
INCR InterCure	1.1696 of 5 stars	$0.94 -2.2%	N/A	-28.5%	$51.34M	$78.47M	31.30	350	Gap Down
TIL Instil Bio	1.5139 of 5 stars	$7.56 -0.7%	$66.00 +773.0%	-74.7%	$51.27M	N/A	N/A	410
PDSB PDS Biotechnology	2.4958 of 5 stars	$0.91 -5.3%	$9.00 +890.1%	-40.8%	$50.74M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CALC) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CalciMedica (CALC) Competitors

CALC vs. KALA, INCR, TIL, PDSB, and TLPH

How does CalciMedica compare to KALA BIO?

Summary

How does CalciMedica compare to InterCure?

Summary

How does CalciMedica compare to Instil Bio?

Summary

How does CalciMedica compare to PDS Biotechnology?

Summary

How does CalciMedica compare to Talphera?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC vs. The Competition

CalciMedica Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CalciMedica (CALC) Competitors

CALC vs. KALA, INCR, TIL, PDSB, and TLPH

How does CalciMedica compare to KALA BIO?

Which has more volatility & risk, KALA or CALC?

Which has stronger earnings & valuation, KALA or CALC?

Does the media prefer KALA or CALC?

Is KALA or CALC more profitable?

Do insiders & institutionals hold more shares of KALA or CALC?

Do analysts rate KALA or CALC?

Summary

How does CalciMedica compare to InterCure?

Which has better valuation & earnings, INCR or CALC?

Which has more risk and volatility, INCR or CALC?

Do analysts rate INCR or CALC?

Does the media favor INCR or CALC?

Is INCR or CALC more profitable?

Do insiders and institutionals hold more shares of INCR or CALC?

Summary

How does CalciMedica compare to Instil Bio?

Which has more risk and volatility, TIL or CALC?

Do analysts prefer TIL or CALC?

Which has higher earnings & valuation, TIL or CALC?

Does the media prefer TIL or CALC?

Is TIL or CALC more profitable?

Do institutionals & insiders have more ownership in TIL or CALC?

Summary

How does CalciMedica compare to PDS Biotechnology?

Which has more volatility and risk, CALC or PDSB?

Which has stronger valuation & earnings, CALC or PDSB?

Do insiders & institutionals hold more shares of CALC or PDSB?

Does the media refer more to CALC or PDSB?

Do analysts prefer CALC or PDSB?

Is CALC or PDSB more profitable?

Summary

How does CalciMedica compare to Talphera?

Do analysts recommend CALC or TLPH?

Does the media favor CALC or TLPH?

Which has better earnings & valuation, CALC or TLPH?

Is CALC or TLPH more profitable?

Do insiders and institutionals hold more shares of CALC or TLPH?

Which has more volatility and risk, CALC or TLPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC vs. The Competition

CalciMedica Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools